The trajectory of the erectile dysfunction drug presents a intricate picture for shareholders. While the initial introduction generated substantial gains, the end of its intellectual property protection opened the avenue to generic competitors, dramatically eroding revenue. This presents a specific risk for firms depending on comparable blockbuster

The legacy of Viagra, and its developer copyright, presents a complex case study for investors. At first a blockbuster drug, yielding billions in revenue , its patent expiration created a wave of lower-priced alternatives , significantly eroding its market share . While some businesses may seek to capitalize on male sexual dysfunction, the present